Mir-17-92 Cluster Dysregulation in Lymphoid Malignancies: Its Role in Limphomagenesis

Alejandro Roisman and Irma Slavutsky*
Laboratory of Genetics of Lymphoid Neoplasms, Institute of Experimental Medicine, Argentina

*Corresponding author: Irma Slavutsky, Laboratory of Genetics of Lymphoid Neoplasms, Institute of Experimental Medicine, Argentina

Published: 20 Feb, 2017
Cite this article as: Roisman A, Slavutsky I. Mir- 17-92 Cluster Dysregulation in Lymphoid Malignancies: Its Role in Limphomagenesis. Clin Oncol. 2017; 2: 1210.


MicroRNAs (miRNAs) are short, endogenous singled-stranded noncoding RNAs whose dysregulation has been implicated in important biologic processes, including cancer development. The principal mechanism of action of these master regulators is to control gene expression by suppressing mRNA translation and reducing mRNA stability. In particular, the miR-17-92 cluster is one of the most frequently miRNA expressed in different subtypes of non-Hodgkin lymphomas. Its widespread dysregulation in these pathologies suggests this cluster as a new biomarker that may supplement lymphoma diagnosis and prognosis, and also as an attractive target to design novel strategies for cancer therapy.


microRNAs (miRNAs) are small non-coding single-stranded RNAs of 17-25 nucleotides in length that play central regulatory functions in gene expression and transcriptional control by targeting mRNAs and triggering its degradation and/or translational interference [1]. They are involved in important biologic processes, and its dysregulation has been associated with the pathogenesis of several diseases including tumor development and maintenance [2]. Some miRNAs are located in genomic regions involved in chromosomal alterations related to cancer and causally implicated in oncogenesis, acting as tumor suppressor genes or oncogenes [3].
In this context, experimental data have demonstrated the oncogenic properties of miR17-92 polycistronic cluster in both hematological malignancies and solid tumors. This cluster is located in a region of 800 bp in the non-protein-coding gene C13 or f25 at 13q31.3 (4) that encodes for six distinct miRNAs (miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1, and miR-92a-1). They constitute three families according to miRNA seed sequences: miR-17 (miR-17, miR-20a and miR- 18a), miR-19 (miR-19a and miR-19b-1), and miR-92. miR-17-92 cluster also presents two paralogs: miR-106a-363 on chromosome X and miR-106b-25 on chromosome 7. All these miRNAs show high sequence conservation across species suggesting evolutionary pressure to maintain such organization [5]. As a strong oncogene, miR-17-92 regulates multiple cellular processes that favor malignant transformation [6], mainly due to gene amplification and MYC-mediated transcriptional upregulation [7,8]. Particularly, miR-17-92 drives lymphomagenesis by suppressing the expression of multiple negative regulators of the PI3K (Phosphatidylinositide 3-kinase) and NF-κB (nuclear factor kappa B) pathways, and by inhibiting apoptosis [8].
Specific miRNAs characterize various subtypes of Non-Hodgkin Lymphomas (NHLs) and have essential roles in differentiation and lymphomagenesis. Among them, the miR-17-92 cluster is the most frequently over-expressed in B-cell NHLs [9], including Diffuse Large B-cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL) and Burkitt Lymphoma (BL) [8].
In reference to MCL, different authors showed miR-17-92 cluster up regulation in this entity [10,11]. Particularly, Navarro, et al. [10] found miR-17 and miR-20a over expression with high MYC mRNA levels in tumors with a more aggressive clinical behavior, distinguishing two subgroups of MCL patients with different miR expression profiles associated to biological features. More recently, we have explored gene expression patterns of SOXC cluster and, miR17, miR18a, miR19b and miR92a members of the miR17-92 cluster and evaluated their correlation with biological and clinical characteristics of the disease [12]. Interestingly, unsupervised hierarchical clustering analysis revealed two distinctive subsets of tumors showing significant differences in important clinical variables: Cluster A associated with high expression of SOX11, SOX12, miR19a and miR92a signature linked to more aggressive disease and short survival, and Cluster B with SOX4, miR17 and miR18a over expression, exhibiting a reduced proliferating signature and a significantly better prognosis with longer overall survival. This combined analysis of coding and non coding genes in MCL represent a new approach that may contribute to improve the understanding of this pathology. In addition, experimental studies showed that over expression of miR-17-92 mediates chemo- and radioresistance and enhances tumor growth in MCL cells, suggesting this cluster as a potential therapeutic target for patients with this lymphoma [13,14].
Studies on CLL patients found increased miR17 expression in unmutated and ZAP-70 positive cases [15]. Furthermore, a diminished miR-17 activity was seen in patients with TP53 mutation/ deletion [16], results that agree with those observed by Li et al. [17] that found low miR-17 and miR-20a and high miR-19a, miR-19b-1 and miR-92a-1 mRNA levels in cases with TP53 alterations in comparison with healthy donors. In addition, there are evidences of the induction of miR-17-92 expression associated with MYC expression induced by the micro environmental, supporting the impact of these stimuli in miRNAs transcriptional regulation [18] as well as the interaction between MYC and miR-17-92 cluster in CLL patients [15]. MYC is a transcription factor that has a key role in promoting tumorigenesis by activating and repressing target genes involved in many pathways associated to malignant development, being one of the most common abnormalities in cancer [19].
As known, DLBCL is the most common type of NHLs, showing three different molecular subtypes with distinct genetic aberrations and clinical outcome. Among them, the miR-17-92 cluster is significantly upregulated in germinal center B-cell (GCB) subtype compared to activated B-cell [20,21], whereas miR-17 is overexpressed in DLBCL originated within the central nervous system [22]. GCBDLBCL frequently shows amplifications at 13q31.3 region that could be the cause of miR-17-92 upregulation [7]. This mechanism is also observed in patients with Richter´s syndrome, in which 13q31.3 amplifications are observed at the time of transformation, associated to the gain of MYC and loss of TP53, supporting the involvement of the miR-17-92 cluster in the acquisition of a more biologically aggressive disease [23]. MYC binds to the promoter of the miR-17-92 cluster and to the E2F1 promoter (a transcription factor that promotes G1-to-S phase progression) activating their transcription, while the miR-17-92 repress the expression of E2F1, indicating the presence of a fine-tuned regulatory mechanism of proliferation [24]. In addition, miR-17-92 cluster also impacts on B-Cell Receptor (BCR) signaling. Microarray studies showed MYC and MIR17HG loci amplifications, consistent with the high level of MYC and members of miR-17-92 cluster required for DLBCLs to sustain BCR response, suggesting a lymphomagenic feed-forward regulatory loop in this pathology [25].
Consistent with those reported for other NHL subtypes, studies in BL pediatric patients, an aggressive disease characterized by reciprocal translocations of MYC with the immunoglobulin genes, found 13q31 amplification and higher levels of miR17, associated to a tendency for early relapse, confirming the importance of MYC/miR17-92 axis in lymphoma development [26,27].
Although the number miRNAs analysis in primary cutaneous lymphomas is limited, some reports have evaluated the miR-17- 92 cluster expression. A recent study in primary cutaneous B-cell lymphomas [28] found miR-106a (paralog), miR-20a and miR-20b over expression as well as the down regulation of PTEN (Phosphatase and tensin homolog) tumor suppressor gene associated to disease progression. Interestingly, a new study of our group [29] in patients with Mycosis Fungoides (MF), the most frequent Cutaneous T-Cell Lymphoma (CTCL), found higher levels of miR17, miR18a, miR19b and miR92a in patients compared to controls. The analysis according to morphological subtypes showed miR17 and miR-18a over expression in tumoral MF, meanwhile miR19b and mir92a exhibited increased levels in folliculotropic and transformed MFs. In addition, miRNA gene expression profiles showed that miR17 and miR19b were upregulated in patients with deletion of 9p21.3 (CDKN2A) and/or 8q24.21 (MYC) gains, providing new insights in the comprehension of MF pathobiology. In line with our results, Ralfkiaer, et al. [30] also found enhanced expression of miR-17- 92 paralogs, miR-106a/363 and miR-106b/25, in advanced disease compared with early MF, suggesting a role for these miRs in disease progression. Previous reports [31,32] showed that miR106b/25 is also upregulated in Sézary Syndrome, a rare and aggressive variant of CTCL, indicating a potential oncogenic function for this miR17- 92 paralog. In contrast Ballabio, et al. [33] found down regulation of miR17, miR19a, miR92 and miR106a in this pathology, diminishing apoptosis rates and enhancing proliferation. More studies will clarify this discordant results.
Concluding, the present revision shows the important governing roles of miR-17-92 cluster and its paralogs in lymphoid malignancies. Their widespread dysregulation in these pathologies suggests they may be considered as new biomarkers that may add new insights in lymphoma diagnosis and prognosis, and also as attractive targets to design novel strategies for cancer therapy.


This work was supported by grants from the National Research Council (CONICET) (PIP-2012-517), the National Agency of Scientific and Technical Promotion (ANPCyT) (PICT-2014-1566) and the National Cancer Institute.


  1. Morris KV, Mattick JS. The rise of regulatory RNA. Nat Rev Genet. 2014; 6: 423-437.
  2. Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. 2015; 6: 321-333.
  3. Fabbri M, Croce CM. Role of microRNAs in lymphoid biology and disease. Curr Opin Hematol. 2011; 4: 266-272.
  4. Ota A, Tagawa H, Karnan S, Tsuzuki S, Karpas A, Kira S, et al. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res. 2004; 64: 3087-3095.
  5. Petrocca F, Vecchione A, Croce CM. Emerging role of miR-106b-25/miR-17-92 clusters in the control of trans¬forming growth factor beta signaling. Cancer Res. 2008; 68: 8191-8194.
  6. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, et al. A microRNA polycistron as a potential human oncogene. Nature. 2005; 435:828-833.
  7. Schneider B, Nagel S, Ehrentraut S, Kaufmann M, Meyer C, Geffers R, et al. Neoplastic MiR-17~92 deregulation at a DNA fragility motif (SIDD). Genes Chrom Cancer. 2012; 51: 219-228.
  8. Jin HY, Oda H, Lai M, Skalsky RL, Bethel K, Shepherd J, et al. MicroRNA-17~92 plays a causative role in lymphomagenesis by coordinating multiple onco¬genic pathways. EMBO J. 2013; 32: 2377-2391.
  9. Lim EL, Marra MA. MicroRNA dysregulation in B-cell non-Hodgkin lymphoma. Blood Lymphatic Cancer: Targets and Therapy. 2013; 3: 25-40.
  10. Navarro A, Beà S, Fernández V, Prieto M, Salaverria I, Jares P, et al. MicroRNA expression, chromosomal alterations, and immunoglobulin variable heavy chain hypermutations in Mantle cell lymphomas. Cancer Res. 2009; 17: 7071-7078.
  11. Iqbal J, Shen Y, Liu Y, Fu K, Jaffe ES, Liu C, et al. Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis. Blood. 2012; 21: 4939-4948.
  12. Roisman A, Huamán Garaicoa F, Metrebian F, Narbaitz M, Kohan D, García Rivello H, et al. SOXC and MiR17-92 gene expression profiling defines two subgroups with different clinical outcome in mantle cell lymphoma. Genes Chrom Cancer. 2016; 55: 531-540.
  13. Jiang P, Rao EY, Meng N, Zhao Y, Wang JJ. MicroRNA-17-92 significantly enhances radioresistance in human mantle cell lymphoma cells. Radiat Oncol. 2010; 5: 100.
  14. Rao E, Jiang C, Ji M, Huang X, Iqbal J, Lenz G, et al. The miRNA-17∼92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. Leukemia. 2012; 5: 1064-1072.
  15. Bomben R, Gobessi S, Dal BM, Volinia S, Marconi D, Tissino E, et al. The miR-17-92 family regulates the response to Toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes. Leukemia. 2012, 26:1584-1593.
  16. Mraz M, Malinova K, Kotaskova J, Pavlova S, Tichy B, Malcikova J, et al. miR-34a, miR-29c and miR-17–5p are downregulated in CLL patients with TP53 abnormalities. Leukemia. 2009; 23: 1159-1163.
  17. Li Y, Vecchiarelli-Federico LM, Li YJ, Egan SE, Spaner D, Hough MR, et al. The miR-17-92 cluster expands multipotent hematopoietic progenitors whereas imbalanced expression of its individual oncogenic miRNAs promotes leukemia in mice. Blood. 2012; 119: 4486-4498.
  18. Willimott S, Wagner SD. Stromal cells and CD40 ligand (CD154) alter the miRNome and induce miRNA clus¬ters including, miR-125b/miR-99a/let-7c and miR-17-92 in chronic lymphocytic leukaemia. Leukemia. 2012; 26:1113-1116.
  19. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008; 8: 976-990.
  20. Lawrie CH, Soneji S, Marafioti T, Cooper CD, Palazzo S, Paterson JC, et al. MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int J Cancer. 2007; 121: 1156-1161.
  21. Culpin RE, Proctor SJ, Angus B, Crosier S, Anderson JJ, Mainou-Fowler T. A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines. Int J Oncol. 2010; 37: 367-376.
  22. Robertus JL, Harms G, Blokzijl T, Booman M, de Jong D, van Imhoff G, et al. Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma. Mod Pathol. 2009; 22: 547-555.
  23. Scandurra M, Rossi D, Deambrogi C, Rancoita PM, Chigrinova E, Mian M, et al. Genomic profil¬ing of Richter’s syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas. Hematol Oncol. 2010; 28: 62-67.
  24. O’Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature. 2005; 435: 839-843.
  25. Psathas JN, Doonan PJ, Raman P, Freedman BD, Minn AJ, Thomas-Tikhonenko A. The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop. Blood. 2013; 122: 4220-4229.
  26. Schiffman JD, Lorimer PD, Rodic V, Jahromi MS, Downie JM, Bayerl MG, et al. Genome wide copy number analysis of paediatric Burkitt lym¬phoma using formalin-fixed tissues reveals a subset with gain of chromosome 13q and corresponding miRNA over expression. Br J Haematol. 2011; 155: 477-486.
  27. Robaina MC, Faccion RS, Mazzoccoli L, Rezende LM, Queiroga E, Bacchi CE, et al. miR-17-92 cluster components analysis in Burkitt lymphoma: overexpression of miR-17 is associated with poor prognosis. Ann Hematol 2016; 95: 881-891.
  28. Battistella M, Romero M, Castro-Vega L-J, Gapihan G, Bouhidel F, Bagot M, et al. The high expression of the microRNA 17–92 cluster and its paralogs, and the downregulation of the target gene PTEN, is associated with primary cutaneous B-Cell lymphoma progression. J Invest Dermatol. 2015; 135: 1659–1667.
  29. Huamán Garaicoa F, Roisman A, Arias M, Trila C, Fridmanis M, Abeldaño A, et al. Genomic imbalances and microRNA transcriptional profiles in patients with mycosis fungoides. Tumour Biol. 2016; 37: 13637-13647.
  30. Ralfkiaer U, Hagedorn PH, Bangsgaard N, Løvendorf MB, Ahler CB, Svensson L, et al. Diagnostic microRNA profiling in cutaneous T-cell lymphoma. Blood. 2011; 118: 5891-5900.
  31. Narducci MG, Arcelli D, Picchio MC, Lazzeri C, Pagani E, Sampogna F, et al. MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in Sezary syndrome. Cell Death Dis. 2011; 2.
  32. Cristofoletti C, Picchio MC, Lazzeri C, Tocco V, Pagani E, Bresin A, et al. Comprehensive analysis of PTEN status in Sezary syndrome. Blood. 2013; 122: 3511-20.
  33. Ballabio E, Mitchell T, van Kester MS, Taylor S, Dunlop HM, Chi J, et al. MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential. Blood. 2010; 116: 1105-1113.